Myelodysplastic Syndrome
News
Amgen withdraws application for darbepoetin alfa
Amgen has withdrawn its application to expand the existing marketing authorization for darbepoetin alfa (Aranesp), according to the European...
Conference Coverage
Manufactured graft deemed safe in blood cancer patients
LISBON—Phase 1 results suggest a programmed cellular therapy is safe for use in patients with hematologic malignancies. The therapy, ProTmune, is...
Conference Coverage
HSCT approach provides ‘excellent’ survival in FA
SALT LAKE CITY—A “risk-adjusted” approach leads to “excellent” survival in patients with Fanconi anemia (FA) undergoing alternative donor...
Conference Coverage
Expanded UCB product can stand alone
SALT LAKE CITY—The expanded umbilical cord blood (UCB) product NiCord can be used as a stand-alone graft, according to research presented at the...
Conference Coverage
‘Remarkable’ survival seen with pretransplant JAK inhibitor
SALT LAKE CITY – Pretransplant JAK inhibitor therapy may improve posttransplant survival in patients with myelofibrosis, according to a phase 2...
News
NK-cell therapy in resistant MDS, AML
Results of a phase 1/2 trial suggest treatment with haploidentical natural killer (NK) cells can be effective against relapsed/refractory...
News
Azacitidine now available in China
Azacitidine for injection (Vidaza®) is now available in China. The nucleoside metabolic inhibitor was approved in China to treat patients with...
From the Journals
Sotatercept promising for treatment of anemia in MDS
The phase 2 trial included patients who did not respond to erythropoiesis-stimulating agents.
Conference Coverage
RELAZA2: MRD-guided azacitidine reduces relapse risk in MDS and AML
MRD-guided azacitidine therapy reduces hematological relapse in patients with MDS or AML at high risk for relapse, according to RELAZA2 trial...
News
Predicting response to AZA in MDS, CMML
Researchers have developed a technique that may help predict whether patients with myelodysplastic syndromes (MDS) or chronic myelomonocytic...
Conference Coverage
Novel JAK1 inhibitor shows promise for myeloid malignancies
ATLANTA – A novel JAK1 inhibitor shows encouraging activity, particularly with azacitidine, in certain patients with advanced myeloid malignancies...